Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
369
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression

Emily Symesa Department of Pathology, University of Chicago, Chicago, IL, USA
,
Peng Wanga Department of Pathology, University of Chicago, Chicago, IL, USA
,
Angela M. Lagerb Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
,
Michael R. Bishopb Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA;c The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0001-9256-0328
ORCID Icon,
Barina Aqild Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
&
Girish Venkataramana Department of Pathology, University of Chicago, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8674-2608
ORCID Icon
Pages 2735-2738 | Received 10 Apr 2022, Accepted 30 May 2022, Published online: 18 Jun 2022

References

  • Venkataraman G, Song JY, Tzankov A, et al. Aberrant T-cell antigen expression in classical hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood. 2013;121(10):1795–1804.
  • Barnhard S, Pai A, Chew HK, et al. Richter’s syndrome with aberrant CD2 and CD4 expression. J Clin Oncol. 2012;30(26):e243–5.
  • Tsuyama N, Ennishi D, Yokoyama M, et al. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. Oncotarget. 2017;8(20):33487–33500.
  • Kingma DW, Imus P, Xie XY, et al. CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms. Cytometry. 2002;50(5):243–248.
  • Kaleem Z, White G, Zutter MM. Aberrant expression of T-cell-associated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol. 2001;115(3):396–403.
  • Ahmad E, Steinberg SM, Goldin L, et al. Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2008;74(4):221–226.
  • Doytcheva K, Lager A, Venkataraman G. De novo PD-1-expressing large B-cell lymphoma outside the setting of CLL: possible origin from CD5 + /PD-1 + regulatory B-cell subset. J Hematopathol. 2021;14(4):309–311.
  • Grzywnowicz M, Zaleska J, Mertens D, et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One. 2012;7(4):e35178.
  • Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953–963.
  • He R, Ding W, Viswanatha DS, et al. PD-1 expression in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness. Am J Surg Pathol. 2018;42(7):843–854.
  • Behdad A, Griffin B, Chen YH, et al. PD-1 is highly expressed by neoplastic B-cells in richter transformation. Br J Haematol. 2019;185(2):370–373.
  • Wang Y, Sinha S, Wellik LE, et al. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021;11(5):86.
  • Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419–3427.
  • Ding W. Richter transformation in the era of novel agents. Hematology Am Soc Hematol Educ Program. 2018;2018(1):256–263.
  • Rogers KA, Huang Y, Dotson E, et al. Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic Centre. Br J Haematol. 2019;185(2):363–366.
  • Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239–43.
  • Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–3401.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.